Results 131 to 140 of about 27,184 (256)

Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States

Infectious Diseases and Therapy
Introduction HIV/hepatitis B virus (HBV) coinfection elevates the risk of liver-related complications compared to HIV or HBV mono-infections. While some antiretroviral therapy (ART) regimens slow liver disease progression, the long-term effects of ...
Ching-Yi Chuo, Woodie Zachry, Melanie de Boer, Laura Telep, Li Tao   +4 more
doaj   +1 more source

Treatment Persistence and Switch Among Medicare-Insured People with HIV and Gaps in Care

Infectious Diseases and Therapy
Introduction Adherence to antiretroviral therapy (ART) is crucial for people with HIV (PWH) to maintain health. The Medicare program insures a substantial proportion of PWH in the United States; however, few studies have evaluated ART treatment patterns ...
Suying Li, Uche Mordi, Mary J. Christoph, Haifeng Guo, David T. Gilbertson, Tianye Cui, Travis Lim, Neia Prata Menezes, Woodie Zachry, Phyllis C. Tien   +9 more
doaj   +1 more source

Tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana [PDF]

, 2015

core   +1 more source

Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report [PDF]

, 2016
Kentaro Iwata, Manabu Nagata, Shinichi Nishi, Shuhei Watanabe   +3 more
core   +1 more source

Tenofovir alafenamide/tenofovir disoproxil fumarate

Reactions Weekly, 2021
openaire   +1 more source

Successful Treatment of Progressive Multifocal Leukoencephalopathy With Tenofovir Alafenamide Fumarate. [PDF]

Neurol Neuroimmunol Neuroinflamm
Torkildsen Ø, Bru ANS, Behzadi GIN, Myhr KM.   +3 more
europepmc   +1 more source

Brief Report: Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results From IMPAACT 2010/VESTED. [PDF]

J Acquir Immune Defic Syndr
Nguyen T, Chae JW, Ziemba L, Coletti A, Knowles K, Johnston B, Jean-Philippe P, Mhembere T, Chawana T, Wabwire D, Korutaro V, Moyo S, Mandima P, Sibisi S, Violari A, Hanley S, Mmbaga B, Masheto G, Ponatshego P, Theron G, Naik SN, Shapiro R, Lockman S, Chinula L, Momper JD, IMPAACT 2010/VESTED Protocol Team.   +25 more
europepmc   +1 more source

The benefits and risks of PrEP and kidney function. [PDF]

, 2016
Mocroft, A, Ryom, L
core   +1 more source

Tenofovir alafenamide fumarate use for HIV pre-exposure prophylaxis and weight gain. [PDF]

Sci Rep
Shi F, Xia H, Weissman S, Li X, Yang X.
europepmc   +1 more source

Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use [PDF]

, 2015

core   +1 more source